Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros








Base de dados
Intervalo de ano de publicação
1.
Intern Med ; 55(7): 775-8, 2016.
Artigo em Inglês | MEDLINE | ID: mdl-27041163

RESUMO

A 72-year-old woman with a history of type 2 diabetes mellitus was brought to the ER with metformin-associated lactic acidosis. She received continuous hemofiltration and hemodialysis, but the laboratory analyses showed no improvement. She died 11 hours after admission. Metformin is minimally bound to proteins and is readily dialyzable, but a prolonged period of dialysis is required, because metformin has a very large distribution volume and is distributed to multiple compartments. The peak blood metformin level was 432 mg/L in this case, which is one of the highest metformin concentrations ever reported, and eight hours of hemodialysis were not sufficient to reduce the serum level.


Assuntos
Acidose Láctica/induzido quimicamente , Acidose Láctica/terapia , Diabetes Mellitus Tipo 2/tratamento farmacológico , Hemodiafiltração , Hipoglicemiantes/efeitos adversos , Metformina/efeitos adversos , Idoso , Diabetes Mellitus Tipo 2/fisiopatologia , Evolução Fatal , Feminino , Hidratação , Humanos , Hipoglicemiantes/administração & dosagem , Metformina/administração & dosagem , Vasoconstritores/administração & dosagem , Vasopressinas/administração & dosagem
2.
Ann Pharmacother ; 45(1): e1, 2011 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-21228393

RESUMO

OBJECTIVE: To report a case of myoclonus that developed after administration of dextromethorphan. CASE SUMMARY: A 64-year-old man was diagnosed with chronic renal failure due to diabetic nephropathy. The patient started on peritoneal dialysis 6 months before he was hospitalized. Two days before hospitalization, he developed cough and sputum and he visited an outpatient clinic, where dextromethorphan was prescribed. After taking a total of 30 mg of dextromethorphan, the patient developed myoclonus, tremor, agitation, slurred speech, and diaphoresis, which continued after he stopped taking the prescribed medicine. He visited an emergency department and was hospitalized for examination and treatment of myoclonus. DISCUSSION: As the patient's dialysis schedule was adequate, these symptoms were likely not due to uremia. The blood concentration of dextromethorphan (2.68 ng/mL) 60 hours after the 30-mg dose was higher than expected, and the blood concentration of dextrorphan, a metabolite, was lower than expected. We suspected that myoclonus was due to dextromethorphan-related symptoms induced by CYP2D6, which primarily metabolizes dextromethorphan. We analyzed the CYP2D6 gene for polymorphisms and identified CYP2D6 (*)1/(*)10. The patient had been taking metoprolol 40 mg/day for 2 years. The blood concentration of metoprolol 6 hours after administration was 13 ng/mL, which suggests that it was metabolized normally. Metoprolol has another metabolic pathway, via CYP2C19, and this may have led to its lack of accumulation. Moreover, metoprolol may have bound to active CYP2D6. Thus, affinity for CYP2D6, protein-binding rate, and lipid solubility may influence these drug interactions. Total scores for the Adverse Drug Reaction (ADR) probability scale and the Drug Interaction Probability Scale (DIPS) were 9 (highly probable) and 3 (possible), respectively. CONCLUSIONS: Myoclonus and other symptoms in this patient may have been caused by a prolonged high concentration of dextromethorphan due to CYP2D6 polymorphisms and drug interactions.


Assuntos
Antitussígenos/efeitos adversos , Dextrometorfano/efeitos adversos , Falência Renal Crônica/terapia , Mioclonia/induzido quimicamente , Diálise Peritoneal , Síndrome da Serotonina/diagnóstico , Antagonistas Adrenérgicos beta/efeitos adversos , Antagonistas Adrenérgicos beta/sangue , Antagonistas Adrenérgicos beta/uso terapêutico , Anti-Hipertensivos/efeitos adversos , Anti-Hipertensivos/sangue , Anti-Hipertensivos/uso terapêutico , Antitussígenos/sangue , Antitussígenos/uso terapêutico , Tosse/complicações , Tosse/tratamento farmacológico , Citocromo P-450 CYP2D6/genética , Dextrometorfano/sangue , Dextrometorfano/uso terapêutico , Diagnóstico Diferencial , Interações Medicamentosas , Genótipo , Humanos , Hipertensão/complicações , Hipertensão/tratamento farmacológico , Falência Renal Crônica/complicações , Masculino , Metoprolol/efeitos adversos , Metoprolol/sangue , Metoprolol/uso terapêutico , Pessoa de Meia-Idade , Mioclonia/sangue , Síndrome da Serotonina/genética
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA